GlassScriptPhysician profile
Shelly E Lomax
NPI 1528410461
$6,004.99
in general payments reported to CMS, 2019-2025
28 companies · $885 in 2025
The $885 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $326 · 2021: $736 · 2022: $886 · 2023: $1,330 · 2024: $1,171 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,251 · Entertainment: $114 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.42 |
| Entertainment | $113.97 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $733.12 | 2019-2023 | Acuvue |
| Sun Pharmaceutical Industries INC. | $544.32 | 2019-2025 | |
| Alcon Vision LLC | $487.29 | 2020-2025 | Rocklatan, Rhopressa, Simbrinza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $451.67 | 2019-2021 | |
| Coopervision INC. | $336.20 | 2021-2025 | Myday Contact Lens, Misight Contact Lens |
| Biotissue Holdings INC. | $317.53 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $303.88 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $287.52 | 2019-2022 | |
| Dompe US, INC. | $269.81 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $254.51 | 2023-2024 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $252.61 | 2022-2023 | Acthar |
| Sight Sciences, INC. | $249.91 | 2019-2022 | |
| Abbvie INC. | $183.84 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $182.69 | 2020-2023 | |
| Amgen INC. | $165.06 | 2024-2025 | Tepezza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $141.27 | 2019 | |
| Apellis Pharmaceuticals, INC. | $121.84 | 2024 | Syfovre |
| Horizon Therapeutics Plc | $120.00 | 2023 | Tepezza |
| Optos, INC. | $113.97 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Lkc Technologies, INC. | $102.74 | 2024 | |
| Integra Lifesciences Corporation | $85.32 | 2019 | |
| Harrow Eye, LLC | $81.86 | 2024-2025 | Vevye, Iheezo |
| Tarsus Pharmaceuticals, INC. | $63.84 | 2025 | Xdemvy |
| Carl Zeiss Meditec USA, INC. | $57.58 | 2021 | |
| Rayner Intraocular Lenses Limited | $36.75 | 2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Thea Pharma INC. | $29.25 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Kala Pharmaceuticals, INC. | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelly Lomax listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.